Personalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality?
作者信息
Platzbecker Uwe, Fenaux Pierre
机构信息
Universitätsklinikum "Carl-Gustav-Carus", Medizinische Klinik I, Technische Universität Dresden, Dresden, Germany
Service d'Hématologie Sénior, Hopital Saint Louis, Assistance Publique-Hôpitaux de Paris et Université Paris 7, France.
出版信息
Haematologica. 2015 May;100(5):568-71. doi: 10.3324/haematol.2015.126813.
Abstract
摘要
相似文献
1
Personalized medicine in myelodysplastic syndromes: wishful thinking or already clinical reality?骨髓增生异常综合征中的个性化医疗：一厢情愿还是已然成为临床现实？
Haematologica. 2015 May;100(5):568-71. doi: 10.3324/haematol.2015.126813.
2
Myelodysplastic syndromes: state of the art pathology, diagnosis and management.骨髓增生异常综合征：最新的病理学、诊断与管理
Best Pract Res Clin Haematol. 2013 Dec;26(4):307-8. doi: 10.1016/j.beha.2014.01.002. Epub 2014 Jan 20.
3
Management of myelodysplastic syndromes: just the beginning.骨髓增生异常综合征的管理：这只是开始。
Oncology (Williston Park). 2008 Nov 15;22(12):1360, 1363, 1368.
4
Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): consensus statements and report from an expert workshop.骨髓增生异常综合征 (MDS) 患者的诊断和预后评估进展更新：专家研讨会的共识声明和报告。
Leuk Res. 2012 Mar;36(3):264-70. doi: 10.1016/j.leukres.2011.11.005. Epub 2011 Dec 3.
5
[Treatment of myelodysplastic syndrome by integrative medicine: a review].[中西医结合治疗骨髓增生异常综合征的综述]
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 May;33(5):717-20.
6
[Current management of myelodysplastic syndromes].
Rev Med Suisse. 2011 Aug 31;7(306):1634, 1636-8, 1640-3.
7
[Management of patients with lower risk myelodysplastic syndromes].
Zhonghua Xue Ye Xue Za Zhi. 2012 Jul;33(7):509-10.
8
[Management options of patients with intermediate and high risk myelodysplastic syndromes].[中高危骨髓增生异常综合征患者的管理选择]
Zhonghua Xue Ye Xue Za Zhi. 2012 Jul;33(7):508.
9
[The cutting-edge of medicine; myelodysplastic syndromes--recent development in diagnosis and treatment].[医学前沿；骨髓增生异常综合征——诊断与治疗的最新进展]
Nihon Naika Gakkai Zasshi. 2011 Nov 10;100(11):3346-53. doi: 10.2169/naika.100.3346.
10
[Clinical aspect of myelodysplastic syndromes (MDS)].骨髓增生异常综合征（MDS）的临床方面
Nihon Naika Gakkai Zasshi. 2000 Mar 10;89(3):550-3.
引用本文的文献
1
Patient stratification in myelodysplastic syndromes: how a puzzle may become a map.骨髓增生异常综合征的患者分层：谜题如何变成地图。
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):418-425. doi: 10.1182/hematology.2020000126.
2
Recent frustration and innovation in myelodysplastic syndrome.骨髓增生异常综合征的近期挫折与创新
Haematologica. 2016 Aug;101(8):891-3. doi: 10.3324/haematol.2016.142836.
本文引用的文献
1
Age-related clonal hematopoiesis associated with adverse outcomes.与不良预后相关的年龄相关性克隆性造血。
N Engl J Med. 2014 Dec 25;371(26):2488-98. doi: 10.1056/NEJMoa1408617. Epub 2014 Nov 26.
2
Myelodysplasia is in the niche: novel concepts and emerging therapies.骨髓发育异常处于特定环境中：新概念与新兴疗法。
Leukemia. 2015 Feb;29(2):259-68. doi: 10.1038/leu.2014.325. Epub 2014 Nov 14.
3
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?修订后的国际预后评分系统（IPSS）能否预测经典IPSS低危或中危-1骨髓增生异常综合征（MDS）患者对促红细胞生成素刺激剂的反应？
Blood. 2013 Sep 26;122(13):2286-8. doi: 10.1182/blood-2013-07-512442.
4
Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.分子突变对骨髓增生异常综合征及相关肿瘤中 DNMT 抑制剂治疗反应的影响。
Leukemia. 2014 Jan;28(1):78-87. doi: 10.1038/leu.2013.269. Epub 2013 Sep 18.
5
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.成人原发性骨髓增生异常综合征的诊断和治疗：欧洲白血病网络的建议。
Blood. 2013 Oct 24;122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26.
6
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.对伴有 del(5q)的骨髓增生异常综合征使用来那度胺的反应：细胞遗传学和突变的影响。
Br J Haematol. 2013 Jul;162(1):74-86. doi: 10.1111/bjh.12354. Epub 2013 Apr 25.
7
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.阿扎胞苷与来那度胺序贯联合治疗伴有del(5q)的高危骨髓增生异常综合征或急性髓系白血病：一项I期研究。
Leukemia. 2013 Jun;27(6):1403-7. doi: 10.1038/leu.2013.26. Epub 2013 Jan 28.
8
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.骨髓增生异常综合征中的 TP53 突变与 5 号染色体异常密切相关，并与不良预后相关。
Br J Haematol. 2013 Mar;160(5):660-72. doi: 10.1111/bjh.12203. Epub 2013 Jan 9.
9
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes.异基因造血细胞移植治疗骨髓增生异常综合征。
Semin Hematol. 2012 Oct;49(4):342-9. doi: 10.1053/j.seminhematol.2012.07.003.
10
Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.来那度胺治疗 5q- 与非 5q- 骨髓增生异常综合征。
Semin Hematol. 2012 Oct;49(4):312-22. doi: 10.1053/j.seminhematol.2012.07.001.
Zotero 插件